SpineX has received funds to complete a pivotal clinical trial of the SCiP device in children with cerebral palsy (CP), a movement disorder in childhood.
The National Institutes of Health, through the Small Business Innovation Research Awards, has provided the funding.
In the pivotal trial, the company will test the safety and efficacy of the SCiP device.
The data obtained from the trial will be used by the company to seek approval from the US Food and Drug Administration (FDA) for marketing and further development of the commercial device.
SCiP therapy targets the abnormal connectivity between the brain and spinal cord to treat the root causes of CP.
To date, the therapy has shown durable functional improvements that are significantly greater compared to the existing treatments in children with CP.